scholarly journals Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-related Post-traumatic Stress

2015 ◽  
Vol 107 (7) ◽  
pp. djv099-djv099 ◽  
Author(s):  
K. Hermelink ◽  
V. Voigt ◽  
J. Kaste ◽  
F. Neufeld ◽  
R. Wuerstlein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Traumatic Stress ◽  
Breast Cancer Patients ◽  
Post Traumatic Stress ◽  
Post Traumatic ◽  
The Impact

scholarly journals RE: Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-Related Post-traumatic Stress

2016 ◽  
Vol 108 (8) ◽  
pp. djw048 ◽  
Author(s):  
Amir Ali Sepehry ◽  
Scott Tyldesley ◽  
Margot Kathleen Davis ◽  
Christine Simmons ◽  
Alexander Rauscher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Traumatic Stress ◽  
Breast Cancer Patients ◽  
Post Traumatic Stress ◽  
Post Traumatic ◽  
The Impact

scholarly journals Post-traumatic Stress Symptoms and Serotonin Transporter (5-HTTLPR) Polymorphism in Breast Cancer Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Luigi Zerbinati ◽  
Martino Belvederi Murri ◽  
Rosangela Caruso ◽  
Maria Giulia Nanni ◽  
Wendy Lam ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Serotonin Transporter ◽  
Traumatic Stress ◽  
Breast Cancer Patients ◽  
Post Traumatic Stress ◽  
Event Scale ◽  
Gene Environment ◽  
Post Traumatic ◽  
The Impact

Introduction: Post-traumatic Symptoms (PTSS) and Post-traumatic Stress Disorder (PTSD) have been reported to affect a quite significant proportion of cancer patients. No study has examined the relationship between serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cancer, including Gene-Environment interactions between this polymorphism and specific causes of distress, such as cancer related problems (CRP) or life stressful events (SLE).Methods: One hundred and forty five breast cancer outpatients participated in the study and were assessed using the Impact of Event Scale (IES), the Problem List (PL) developed by the National Comprehensive Cancer Network (NCCN) Distress Management Guidelines and the Paykel's Life Events Interview to evaluate the exposure to SLE during the year before the cancer diagnosis. Each patient was genotyped for 5-HTTLPR polymorphism by analyzing genomic DNA obtained from whole blood cells. Gene-Environment interactions were tested through moderation analysis.Results: Twenty-six patients (17.7%) were classified as PTSS cases using the IES. Genotype and phenotype distributions did not differ across individuals with/without PTSS (genotype: χ2 = 1.5; df = 2; p = 0.3; phenotype χ2 = 0.9; df = 1; p = 0.2). For both the genotype and phenotype model, using CRP as a predictor showed significant gene-environment interactions with IES total score (p = 0.020 and p = 0.004, respectively), with individuals carrying the l/l allele showing a greater probability of experiencing PTSS. No interaction was found in relationship to SLE (p = 0.750).Conclusion: This study showed a significant GEI between CRP and PTSS in breast cancer patients, with carriers of the l/l allele showing indicators consistent with greater sensitivity to stress.

scholarly journals Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients

2017 ◽  
Vol 109 (10) ◽  
Author(s):  
Kerstin Hermelink ◽  
Markus Bühner ◽  
Philipp Sckopke ◽  
Franziska Neufeld ◽  
Judith Kaste ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Traumatic Stress ◽  
Breast Cancer Patients ◽  
Post Traumatic Stress ◽  
Post Traumatic

scholarly journals Cognitive impairment after cytotoxic chemotherapy

2019 ◽  
Vol 7 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Petra Huehnchen ◽  
Antonia van Kampen ◽  
Wolfgang Boehmerle ◽  
Matthias Endres
Keyword(s):  
Breast Cancer ◽  
Colon Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Cytotoxic Chemotherapy ◽  
Cytotoxic Drugs ◽  
Cytotoxic Agents ◽  
Cancer Type ◽  
Breast Cancer Patients ◽  
The Impact

Abstract Background Neurotoxicity is a frequent side effect of cytotoxic chemotherapy and affects a large number of patients. Despite the high medical need, few research efforts have addressed the impact of cytotoxic agents on cognition (ie, postchemotherapy cognitive impairment; PCCI). One unsolved question is whether individual cytotoxic drugs have differential effects on cognition. We thus examine the current state of research regarding PCCI. Neurological symptoms after targeted therapies and immunotherapies are not part of this review. Methods A literature search was conducted in the PubMed database, and 1215 articles were reviewed for predefined inclusion and exclusion criteria. Thirty articles were included in the systematic review. Results Twenty-five of the included studies report significant cognitive impairment. Of these, 21 studies investigated patients with breast cancer. Patients mainly received combinations of 5-fluorouracil, epirubicin, cyclophosphamide, doxorubicin, and taxanes (FEC/FEC-T). Five studies found no significant cognitive impairment in chemotherapy patients. Of these, 2 studies investigated patients with colon cancer receiving 5-fluorouracil and oxaliplatin (FOLFOX). Independent risk factors for PCCI were patient age, mood alterations, cognitive reserve, and the presence of apolipoprotein E e4 alleles. Conclusions There is evidence that certain chemotherapy regimens cause PCCI more frequently than others as evidenced by 21 out of 23 studies in breast cancer patients (mainly FEC-T), whereas 2 out of 3 studies with colon cancer patients (FOLFOX) did not observe significant changes. Further studies are needed defining patient cohorts by treatment protocol in addition to cancer type to elucidate the effects of individual cytotoxic drugs on cognitive functions.

Sign in / Sign up

Export Citation Format

Share Document